Humacyte is trading at $0.40, down 6.15%, with the catalyst unclear. - No clear company-specific announcement explaining the October 19 decline surfaced in the search. - On October 15, Humacyte said hospitals ordering Symvess rose 44%, from 34 to 49; that earlier update does not establish a cause. - The supplied biotech-sector data shows XBI up 2.09%, which does not explain Humacyte’s decline.